Literature DB >> 20492459

Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.

N Garg1, N Goyal, T L Strawn, J Wu, K M Mann, D A Lawrence, W P Fay.   

Abstract

BACKGROUND: Vascular smooth muscle cell (VSMC) migration is a critical process in arterial remodeling. Purified plasminogen activator inhibitor-1 (PAI-1) is reported to both promote and inhibit VSMC migration on two-dimensional (D) surfaces.
OBJECTIVE: To determine the effects of PAI-1 and vitronectin (VN) expressed by VSMC themselves on migration through physiological collagen matrices.
METHODS: We studied migration of wild-type (WT), PAI-1-deficient, VN-deficient, PAI-1/VN doubly-deficient (DKO) and PAI-1-transgenic (Tg) VSMC through three-D collagen gels.
RESULTS: WT VSMC migrated significantly slower than PAI-1- and VN-deficient VSMC, but significantly faster than DKO VSMC. Experiments with recombinant PAI-1 suggested that basal VSMC PAI-1 expression inhibits migration by binding VN, which is secreted by VSMC and binds collagen. However, PAI-1-over-expressing Tg VSMC migrated faster than WT VSMC. Reconstitution experiments with recombinant PAI-1 mutants suggested that the pro-migratory effect of PAI-1 over-expression required its anti-plasminogen activator (PA) and LDL receptor-related protein (LRP) binding functions, but not VN binding. While promoting VSMC migration in the absence of PAI-1, VN inhibited the pro-migratory effect of active PAI-1.
CONCLUSIONS: In isolation, VN and PAI-1 are each pro-migratory. However, via formation of a high-affinity, non-motogenic complex, PAI-1 and VN each buffers the other's pro-migratory effect. The level of PAI-1 expression by VSMC and the concentration of VN in extracellular matrix are critical determinants of whether PAI-1 and VN promote or inhibit migration. These findings help to rectify previously conflicting reports and suggest that PAI-1/VN stoichiometry plays an important role in VSMC migration and vascular remodeling.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492459      PMCID: PMC2941703          DOI: 10.1111/j.1538-7836.2010.03907.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  40 in total

1.  Altered response of vascular smooth muscle cells to exogenous biochemical stimulation in two- and three-dimensional culture.

Authors:  Jan P Stegemann; Robert M Nerem
Journal:  Exp Cell Res       Date:  2003-02-15       Impact factor: 3.905

Review 2.  Type 1 plasminogen activator inhibitor.

Authors:  D J Loskutoff; M Sawdey; J Mimuro
Journal:  Prog Hemost Thromb       Date:  1989

3.  Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque.

Authors:  P Dufourcq; H Louis; C Moreau; D Daret; M R Boisseau; J M Lamazière; J Bonnet
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-02       Impact factor: 8.311

Review 4.  Vascular functions of the plasminogen activation system.

Authors:  William P Fay; Nadish Garg; Madhavi Sunkar
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-03-22       Impact factor: 8.311

5.  Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation.

Authors:  Pascale Dufourcq; Thierry Couffinhal; Philipe Alzieu; Danièle Daret; Catherine Moreau; Cécile Duplàa; Jacques Bonnet
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

6.  The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.

Authors:  Bernard Degryse; Jaap G Neels; Ralf-Peter Czekay; Kathleen Aertgeerts; Yu-Ichi Kamikubo; David J Loskutoff
Journal:  J Biol Chem       Date:  2004-03-04       Impact factor: 5.157

7.  Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein.

Authors:  Yuichi Kamikubo; Jaap G Neels; Bernard Degryse
Journal:  Int J Biochem Cell Biol       Date:  2008-07-25       Impact factor: 5.085

8.  The inhibitory effect and mechanism of luteolin 7-glucoside on rat aortic vascular smooth muscle cell proliferation.

Authors:  Tack-Joong Kim; Jin-Ho Kim; Yong-Ri Jin; Yeo-Pyo Yun
Journal:  Arch Pharm Res       Date:  2006-01       Impact factor: 4.946

9.  Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

Authors:  D T Eitzman; R D McCoy; X Zheng; W P Fay; T Shen; D Ginsburg; R H Simon
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

10.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

Authors:  J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more
  18 in total

1.  Activation of the D4 dopamine receptor attenuates proliferation and migration of vascular smooth muscle cells through downregulation of AT1a receptor expression.

Authors:  Changqing Yu; Jianghua Chen; Weiwei Guan; Yu Han; Wei Eric Wang; Xukai Wang; Hongyong Wang; Pedro A Jose; Chunyu Zeng
Journal:  Hypertens Res       Date:  2015-04-02       Impact factor: 3.872

2.  Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.

Authors:  Mehmet Agirbasli; Mesut Eren; Songul Yasar; Kenan Delil; Fatih Goktay; Ebru Toksoy Oner; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts.

Authors:  Yan Ji; Tammy L Strawn; Elizabeth A Grunz; Meredith J Stevenson; Alexander W Lohman; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-05-12       Impact factor: 8.311

4.  SERPINE1 expression discriminates site-specific metastasis in human melanoma.

Authors:  R Matthew Klein; Daniel Bernstein; Steven P Higgins; Craig E Higgins; Paul J Higgins
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

5.  Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.

Authors:  Yan Ji; Zhen Weng; Philip Fish; Neha Goyal; Mao Luo; Samantha P Myears; Tammy L Strawn; Bysani Chandrasekar; Jianbo Wu; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

6.  Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.

Authors:  Tihami Qureshi; Sumit Goswami; Carlee S McClintock; Matthew T Ramsey; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-12-02       Impact factor: 6.725

7.  Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.

Authors:  M Luo; Y Ji; Y Luo; R Li; W P Fay; J Wu
Journal:  J Thromb Haemost       Date:  2017-11-08       Impact factor: 5.824

8.  TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis.

Authors:  Renee Rawson; Tom Yang; Robert O Newbury; Melissa Aquino; Ashmi Doshi; Braxton Bell; David H Broide; Ranjan Dohil; Richard Kurten; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2016-04-08       Impact factor: 10.793

9.  Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity.

Authors:  Hyejin Jeon; Jong-Heon Kim; Jae-Hong Kim; Won-Ha Lee; Myung-Shik Lee; Kyoungho Suk
Journal:  J Neuroinflammation       Date:  2012-06-29       Impact factor: 8.322

10.  A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.

Authors:  Jie Wu; Lan Li; Huibo Zhang; Yaqi Zhao; Haohan Zhang; Siyi Wu; Bin Xu
Journal:  Oncogene       Date:  2021-06-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.